肝脏线粒体NAD+转运蛋白SLC25A47激活AMPKα介导脂质代谢与肿瘤发生
研究揭示SLC25A47是肝细胞特异性线粒体NAD+转运蛋白,二甲双胍可转录激活其表达且为AMPKα磷酸化所必需。Slc25a47缺失小鼠肝脏脂质、甘油三酯和胆固醇升高,AMPKα磷酸化受抑,核内SREBPs蓄积;过表达则激活AMPKα抑制脂质合成。在二乙基亚硝胺诱导的小鼠肝癌模型中,Slc25a47缺失通过激活哺乳动物雷帕霉素靶蛋白级联促进肝癌发生发展。
要点
- 二甲双胍转录激活Slc25a47表达,且为AMPKα磷酸化所必需
- Slc25a47缺失升高肝脏脂质、甘油三酯和胆固醇,抑制AMPKα磷酸化
- Slc25a47缺失通过激活mTOR级联促进二乙基亚硝胺诱导的小鼠肝癌发生发展
核心结论
- SLC25A47是肝细胞特异性线粒体NAD+转运蛋白,为二甲双胍的药理靶点之一,通过AMPKα调控脂质稳态,可能作为治疗NAFLD和HCC的潜在药物靶点。
研究设计与样本
- 基础研究:二甲双胍处理肝细胞、Slc25a47缺陷与过表达小鼠、二乙基亚硝胺诱导的小鼠HCC模型,以及SLC25A47同源建模与人代谢组数据库虚拟筛选。
主要发现
- 二甲双胍处理肝细胞可转录激活Slc25a47表达,且为AMPKα磷酸化所必需。
- Slc25a47缺陷小鼠肝脏脂质含量、甘油三酯和胆固醇水平升高,AMPKα磷酸化受抑,核内SREBPs蓄积增多,脂肪酸和胆固醇生物合成活性升高。
- 小鼠肝脏过表达Slc25a47可激活AMPKα并抑制脂质合成。
- 二乙基亚硝胺诱导的小鼠HCC模型中,Slc25a47缺失通过激活哺乳动物雷帕霉素靶蛋白级联促进HCC肿瘤发生与发展。
- 同源建模与虚拟筛选显示NAD+为SLC25A47的内源性底物,Slc25a47缺陷小鼠中NAD+依赖性sirtuin 3活性下降,随后AMPKα失活。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AIMS: SLC25A47 was initially identified as a mitochondrial HCC-downregulated carrier protein, but its physiological functions and transport substrates are unknown. We aimed to investigate the physiological role of SLC25A47 in hepatic metabolism. APPROACH RESULTS: In the treatment of hepatocytes with metformin, we found that metformin can transcriptionally activate the expression of Slc25a47 , which is required for AMP-activated protein kinase α (AMPKα) phosphorylation. Slc25a47 -deficient mice had increased hepatic lipid content, triglycerides, and cholesterol levels, and we found that Slc25a47 deficiency suppressed AMPKα phosphorylation and led to an increased accumulation of nuclear SREBPs, with elevated fatty acid and cholesterol biosynthetic activities. Conversely, when Slc25a47 was overexpressed in mouse liver, AMPKα was activated and resulted in the inhibition of lipogenesis. Moreover, using a diethylnitrosamine-induced mouse HCC model, we found that the deletion of Slc25a47 promoted HCC tumorigenesis and development through the activated mammalian target of rapamycin cascade. Employing homology modeling of SLC25A47 and virtual screening of the human metabolome database, we demonstrated that NAD + was an endogenous substrate for SLC25A47, and the activity of NAD + -dependent sirtuin 3 declined in Slc25a47 -deficient mice, followed by inactivation of AMPKα. CONCLUSIONS: Our findings reveal that SLC25A47, a hepatocyte-specific mitochondrial NAD + transporter, is one of the pharmacological targets of metformin and regulates lipid homeostasis through AMPKα, and may serve as a potential drug target for treating NAFLD and HCC.
引用
- Cheng L, Deepak RNVK, Wang G, et al. Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis. Hepatology. 2023. PMID: 36804859. doi:10.1097/HEP.0000000000000314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。